24/7 Market News Snapshot 16 October, 2024 – Phio Pharmaceuticals Corp. Common Stock (NASDAQ:PHIO)

October 16, 2024

DENVER, Colo., 16 October, 2024 (247marketnews.com) – (NASDAQ:PHIO) are discussed in this article.
Phio Pharmaceuticals Corp. has generated significant market interest, with its stock opening at $3.01 and soaring to an impressive $3.535, reflecting a notable intraday gain of approximately 28% from the previous close of $2.76. This formidable rise is accompanied by a substantial trading volume of 584.32K shares, indicating strong investor engagement and a bullish sentiment surrounding the company. Traders are encouraged to monitor Phio Pharmaceuticals closely as its momentum in the biotech sector suggests a promising outlook for both the company and its stakeholders.

In parallel with these market developments, Phio Pharmaceuticals is set to present pioneering data on its novel INTASYL compound, PH-894, at the upcoming 2024 American Society of Gene & Cell Therapy’s Advancing Gene and Cell Therapies for Cancer conference on October 16. This presentation will reveal significant advancements in improving the functionality of Natural Killer (NK) cells, which play a crucial role in the immune system’s fight against cancer.

The PH-894 compound has demonstrated the capability to selectively silence the BRD4 gene within NK cells without adversely affecting their viability. This innovative strategy not only enhances NK cell proliferation during ex vivo expansion but also increases their cytotoxic effectiveness by downregulating the inhibitory receptor CD94. Such findings underscore the potential of PH-894 to significantly elevate the outcomes of NK cell-based adoptive therapies.

Melissa Maxwell will lead the presentation, focusing on how PH-894 could serve as a foundational technology in the development of advanced NK cell immunotherapies. With its unique INTASYL siRNA platform, Phio Pharmaceuticals is dedicated to transforming cancer treatment and remains at the forefront of developing effective immunotherapeutic solutions to combat this pervasive disease. The upcoming conference marks a critical opportunity for Phio to showcase its advancements and commitment to enhancing cancer therapies.

Related news for (PHIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.